FDA Approved: NEOPROFEN — Supplemental Application (Recordati Rare Diseases Inc.)

View source ↗

Summary

The FDA approved a supplemental application for NEOPROFEN (ibuprofen lysine) from Recordati Rare Diseases Inc., expanding its approved use or labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Ductus Arteriosus

Drugs mentioned

• NEOPROFEN (IBUPROFEN LYSINE)

Snippet

SUPPL AP for NEOPROFEN (IBUPROFEN LYSINE)